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ABSTRACT
Introduction: Health technology assessment is
not required for regulatory submission or
approval in either the United States (US) or
Japan. This study was designed as a
cross-country evaluation of cost analyses
conducted in the US and Japan based on the
PRONOUNCE phase III lung cancer trial, which
compared pemetrexed plus carboplatin
followed by pemetrexed (PemC) versus
paclitaxel plus carboplatin plus bevacizumab
followed by bevacizumab (PCB).
Methods: Two cost analyses were conducted in
accordance with International Society For
Pharmacoeconomics and Outcomes Research
good research practice standards. Costs were
obtained based on local pricing structures;
outcomes were considered equivalent based on
the PRONOUNCE trial results. Other inputs
were included from the trial data (e.g., toxicity
rates) or from local practice sources (e.g.,
toxicity management). The models were
compared across key input and transferability
factors.
Results: Despite differences in local input data,
both models demonstrated a similar direction,
with the cost of PemC being consistently lower
than the cost of PCB. The variation in
individual input parameters did affect some of
the specific categories, such as toxicity, and
impacted sensitivity analyses, with the cost
differential between comparators being greater
in Japan than in the US.
Conclusion: When economic models are based
on clinical trial data, many inputs and
outcomes are held consistent. The alterable
inputs were not in and of themselves large
enough to significantly impact the results
between countries, which were directionally
consistent with greater variation seen in
sensitivity analyses. The factors that vary
across jurisdictions, even when minor, can
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INTRODUCTION
Health technology assessment (HTA) is a form
of health care policy research that evaluates the
impact of a health care technology (e.g.,
instrument, medication or procedure) on
society (or a subset of society such as a payer
or patient perspective). It incorporates a range
of methods and approaches that are tailored to
the needs of the health care system in various
countries and considers various aspects of that
impact such as efficacy, toxicity or negative
outcomes, costs, and patient burden or quality
of life [1]. Unlike many parts of the world that
require HTA as part of the process for pricing,
access, and reimbursement, it is not required in
Japan or the United States (US) for regulatory
approval or for reimbursement. Nevertheless,
HTA is conducted and published by industry,
academia, and other groups to compare the
value of treatment options to inform decision
making in these countries. In Japan, HTA is not
yet a required evaluation process for approval,
but there is evidence suggesting that this will be
more important in the not-so-distant future [2,
3]. Japan has a national healthcare system in
which patients pay a portion of the total costs,
and the government or employer (via
insurance) covers the remainder of the costs.
The statutory health insurance system is
administered by a multitude of insurers: the
government (from October 2008, a
quasi-governmental body, the Japan Health
Insurance Association) for employees of small
to medium-sized firms and their dependents,
1584 Society-managed Health Insurance funds
for employees of large firms and their
dependents, 76 Mutual Aid Society (MAS)
funds for government employees and
dependents, 1835 municipal National Health
Insurance funds for the self-employed, retired
and unemployed, and 166 National Health
Insurance Society funds for some occupational
groups such as doctors and lawyers, each with
different premium contribution rates [4]. Japan
relies heavily on hospital care; facilities support
a large number of hospital beds, and patient
care reflects a long average length of stay and
high utilization rates compared with other
regions of the world. National health
expenditures in Japan have increased
significantly since 1961 with the establishment
of the National Health Insurance system for the
entire population. The government has set a
policy goal of controlling the growth of health
expenditures in parallel with national economic
growth to reduce the financial burden on the
population. In 1990, at a time of economic
boom, national health expenditure as a
proportion of GDP was almost 5% [4]. Since
then, economic growth has stagnated and,
therefore, health care costs as a percentage of
national income has increased steadily. Given
the long-lasting economic recession, coupled
with the rapidly aging population, the burden
of health care costs is expected to grow in the
foreseeable future [4].
In comparison to Japan, there are factors that
reduce the urgency of the US government to take
primary responsibility to curb health care
spending. Only a small portion of total health
care costs are currently covered through national
or State government budgets (e.g., Medicare,
Medicaid), and there is no national healthcare
system in the US [1]. Therefore, the value of
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healthcare expenditures has a less direct impact
on the national budget than in other countries;
health care is largely provided by a variety of
for-profit commercial enterprises in the US (i.e.,
there are numerous health insurers, centers,
clinics, hospitals, and providers who must each
make a profit on the provision of health care
services to the public).While some not-for-profit
healthcare organizations exist, the majority of
health care services in the US are part of a
competitive free-market system in which
competition is used to control costs due to
supply and demand; however, there are market
forces in place for health care that cause it to
perform differently from other commodities.
There remains an escalation of per-capita
health care costs as the demand for health care
continually increases with the aging population
and with the increase in chronic diseases.
Insurance can, in part, help to control the
demand for health care through referral and
pre-authorization processes, but this can only be
applied to about half the US population. In the
US approximately 28% are uninsured and an
additional 20% are underinsured, limiting the
influence of insurers to control health care
resource utilization [5]. However, these
numbers are declining with the
implementation of the Affordable Care Act,
which provides access to health care insurance
to those not covered by their employers. In part
due to incomplete insurance coverage, health
care costs are a significant cause of individual
bankruptcy in the US [6, 7]. Despite the burden
of health care costs in the US, there remains a
cultural attitude that prohibits the
implementation of any type of cost per
outcome access restriction and will make any
legislation to restrict access to high-cost services
a difficult strategy to propose by elected officials
[8]. Not only does the US spendmore than Japan
in terms of per-capita health care expenditures
[9], theUS also spends approximately three times
the amount for health care administration than
does Japan [10].
In regions that require HTA research to be
conducted for national approval or
reimbursement decisions, there are standard
guidelines and expectations for the way in
which these studies are to be presented that
differ country by country [e.g., The National
Institute for Health and Care Excellence (NICE)
in the UK, The Institute for Quality and
Efficiency in Health Care (IQWiG) in
Germany]. There are additionally international
standards for the conduct of cost analyses that
guide this type of research for academic and
good research practice purposes [11, 12].
Additionally, there are guidelines for the
transfer of analyses from one country to
another [13]. However, where no regional
requirements exist for HTA, such as in the US
and Japan, there is no straightforward way to
adjust models to apply to the different payer
and regional needs, and researchers must make
decisions about the inputs and unit costs that
are most relevant to the target decision maker.
Two cost-minimization analyses were
conducted in the US and in Japan. The US
model was developed by RTI Health Solutions
and was modified for Japan by PRIMA
Consulting Group to inform evidence-based
decision making regarding the outcomes of
the PRONOUNCE trial (ClinicalTrials.gov
identifier, NCT00948675) [14]. The
PRONOUNCE trial was a phase III randomized
trial comparing two first-line regimens followed
by single-agent maintenance for advanced
non-squamous non-small cell lung cancer
(NSCLC) [15]. This phase III trial found no
significant differences in progression-free
survival (PFS) without grade 4 toxicity, PFS,
overall survival (OS), objective response rate
(ORR), or disease control rate (DCR) between
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pemetrexed plus carboplatin followed by single-
agent pemetrexed (PemC) and paclitaxel plus
carboplatin plus bevacizumab followed by
single-agent bevacizumab (PCB). The two
regimens were similar across all primary and
secondary endpoints.
Based on the results of the PRONOUNCE
trial, the US and Japan cost-minimization
analyses were conducted to estimate the costs
associated PemC versus PCB in each region,
respectively. The US model was developed from
a third-party payer perspective and the Japanese
model was developed from the perspective of
the hospital payer. This study was designed to
compare these models and to explore the
differences in these models to inform the
considerations for transferability of economic
evaluations between the US and Japan in the
context of these two very different health care
system and payment structures.
METHODS
Briefly, the cost-minimization models were
both developed with a focus on direct medical
costs as described below for Japan and the US,
respectively. The medical costs considered
included the costs of drugs, drug
administration and infusion, toxicities,
post-discontinuation therapy, and supportive
care. The unit costs of each input were
multiplied by the amount of the resource used
and then summed to obtain an overall cost for
each treatment in each region. The details of
this approach are presented in the subsections
that follow.
Population
The Japan and US cost models were developed
based on the population of the PRONOUNCE
trial, which is described in detail elsewhere [15].
Eligible patients were age 18 years and older
with a diagnosis of advanced NSCLC (stage IIIB
or IV) that was not amenable to curative
therapy; patients were not allowed to have
received any prior systemic chemotherapy,
immunotherapy, targeted therapy, or
biological therapy for any stage of NSCLC; and
patients had to have an Eastern Cooperative
Oncology Group performance status of 0 or 1 at
the time of study enrollment. Patients were
randomized to receive four cycles of induction
PemC or PCB followed by single-agent
maintenance. Patients were to receive
treatment until the time of disease progression.
As stated earlier, there were no significant
differences between treatment arms for any of
the primary or secondary study aims.
Treatment Comparators and Time
Horizon
Both models included costs associated with the
PRONOUNCE trial regimens of PemC or PCB.
Patients began induction therapy with one of
these two regimens; patients with complete
response, partial response, or stable disease
after four cycles continued onto single-agent
maintenance therapy. The PemC group received
pemetrexed 500 mg/m2 plus carboplatin area
under the curve (AUC) 6 every 21 days for 4
cycles, followed by pemetrexed 500 mg/m2
every 21 days until progressive disease or
treatment discontinuation. The PCB group
received paclitaxel 200 mg/m2 plus carboplatin
AUC 6 plus bevacizumab 15 mg/kg every
21 days for four cycles followed by
bevacizumab 15 mg/kg every 21 days until
progressive disease or treatment
discontinuation [15].
The time horizon of both models was the
length of the PRONOUNCE trial, which was
approximately three years.
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Drug Costs
To estimate the drug acquisition costs
(induction and maintenance) for both models
during the progression-free period, the number
of administrations, as reported in the
PRONOUNCE trial, was combined with
average dosing and unit costs for each drug
within each regimen. The mean number of
administrations was 10.80 [standard error (SE)
0.66] for PemC and 10.5 (SE 0.54) for PCB. The
mean number of induction and maintenance
cycles was 3.45 and 6.80 for PemC, respectively,
and 3.35 and 6.5 for PCB, respectively.
Costs in Japan
Direct medical care costs incurred within
Japanese hospitals were considered for patients
treated with the two study regimens. Unit costs
included in the model are direct medical costs
and are categorized as drug acquisition costs,
administration costs, transfusion costs, and
toxicity costs from the Hokenyaku Jiten (保険
薬辞典), published by Jihou (じほう) and
International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM)
costs (Table 1). Billing arrangements were
based on the payment structure in Japan for
chemotherapy treatment. A case-mix system,
known as Diagnosis Procedure Combination
(DPC) has been introduced, which has helped
in implementing a standardized electronic
claim system, with keywords that provide
transparency and accountability. The DPC is a
case-mix system, which is comparable to the
Diagnosis-Related Groups used in Medicare in
the US. The DPC comprises 18 Major Diagnosis
Categories, 520 diagnostic groups and 2658
case-mix groups. The diagnosis and
comorbidities/complications are coded using
the International Classification of Diseases,
10th Revision, Clinical Modification
(ICD-10-CM) scheme, while the procedures are
coded using the Japanese Procedure Codes as
defined in the fee schedule of the national
health insurance system [16]. For the Japan
model, expert clinical opinion of three
oncologists provided costing estimates on the
clinical care of the toxicity.
Costs in the US
Direct medical costs from a US third-party
perspective are estimated for the
progression-free period as well as for the
post-progression period. Unit costs included in
the model are direct medical costs and are
categorized as drug acquisition costs,
administration costs, transfusion costs, and
toxicity costs from published sources including
the Centers for Medicare and Medicaid Services
[17], the Red Book from Truven Analytics [18],
and Health Care Utilization Project databases
[19]. In the US, the cost of toxicity was assumed
based on hospitalization costs associated with
ICD-9-CM codes reflective of the toxicity.
Treatment Patterns for Both Models
Specific to this model is inputs related directly
to the study treatments, post-discontinuation
therapy, other medical costs, and unit costs.
The clinical trial provided data related to study
treatment and post-discontinuation therapy
(Table 2). Data from the clinical trial included
post-discontinuation therapy, utilization of
granulocyte-colony stimulating factors
(G-CSFs), rate of transfusions, and utilization
of erythropoiesis-stimulating agents (ESAs) [15].
The mean erlotinib dose was assumed to be
150 mg per day as recommended in the package
insert and the standard error was assumed to be
10% of the mean. The mean docetaxel dose was
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Table 1 Inputs for the US and Japan cost models
Input parameter US model value Japan model valueb
Drug acquisition costsa,c
Pemetrexed $5.80 per mg ¥360.45/US$3.69 per mg
Carboplatin $0.07 per mg ¥52.23/US$0.53 per mg
Paclitaxel $0.16 per mg ¥154.74/US$1.58 per mg
Bevacizumab $6.21 per mg ¥433.78/US$4.44 per mg
Docetaxel $9.16 per mg ¥539.55/US$5.53 per mg
Erlotinib $1.28 per mg ¥68.98/US$0.71 per mg
Premedicationsa,c
Folic acid $0.01 per 800-µg tablet ¥9.60/US$0.10 per 5-mg tablet




Dexamethasone $0.10 per 4-mg tablet ¥98.00/US$1.00 per 4-mg injection
Diphenhydramine $2.75 per 50-mg/mL ¥112.00/US$1.15 per 50-mg/mL IV
Cimetidine $3.26 per 300-mg IV ¥112.00/US$1.15 per 300-mg IV
Ranitidine $5.42 per 50-mg IV ¥88.00/US$0.90 per 50-mg IV
Famotidine $0.74 per 20-mg IV ¥92.00/US$0.94 per 20-mg IV
Infusion costsd
Initial infusion (up to 1 h, over 500 mL) $230.50 ¥7250.00/US$74.26
Additional hour $39.13 Not in model
Subsequent infusion $74.69 Not in model
Maintenance infusion (up to 1 h, over500 mL) $230.50 ¥7250.00/US$74.26
G-CSFa,c
Neulasta $3906.04 per 6 mg/0.6 mL
injection
¥495,620.00/US$5076.51 per 6 mg/
0.6 mL injection
Filgastrim Not included in model ¥24,781.00/US$253.83 per 300-µg
injection
Transfusionsd,e
Transfusion administration cost $260.44 ¥500.00/US$5.12
Platelet cost per unit $91.61 ¥7546.00/US$77.29
Fresh frozen plasma $72.23 ¥8706.00/US$89.17
Packed red blood cells $151.79 ¥8169.00/US$83.67
ESAsa,e
Procrit $0.02 per unit ¥1.24/US$0.01 per IU
Epogen $0.14 per unit ¥1.24/US$0.01 per IU
Aranesp $6.43 per µg ¥176.89/US$1.81 per µg
Grade 3–4 toxicity costs (mean costs)f,g
Febrile neutropenia (ICD-9 288.00) $12,006 ¥80,688.90/US$826.48
Adv Ther (2015) 32:1248–1262 1253
calculated from the recommended dose of
75 mg/m2 and the standard error was assumed
to be 10% of the mean. For this calculation, the
average body surface area of lung cancer
patients was taken from the PRONOUNCE trial
[15]. Due to lack of available data on the
amount of use of post-progression treatments
from PRONOUNCE (number of cycles,
combination regimens), all intravenous
systemic therapy in subsequent lines was
assumed to be for three cycles and
administration costs were applied for each
Table 1 continued
Input parameter US model value Japan model valueb
Fatigue (ICD-9 780.79) $6304 ¥28,972.81/US$296.76
Hypertension (ICD-9 401.00) $6095 ¥28,833.70/US$295.34
Thrombosis/thrombus/embolism (ICD-9444.00) $25,729 ¥87.00/US$0.89
Any hemorrhagic events (ICD-9 578.90) $9420 ¥0.00/US$0.00
Neuropathy, sensory (ICD-9 357.60) $8914 ¥29,363.75/US$300.77
Nausea (ICD-9 787.02) $5592 ¥0.00/US$0.00
Vomiting (ICD-9 787.03) $4499 ¥3.36/US$0.03
Anemia (ICD-9 285.30) $6142 ¥7576.10/US$77.60
Neutropenia (ICD-9 288.00) $12,006 ¥20,650.83/$US211.52
Thrombocytopenia (ICD-9 287.31) $16,488 ¥3773.00/US$38.65
Drugs used to manage grade 3–4 toxicityc
G-CSF (Filgrastim) Drugs for toxicity
management not
included in US model
for costs of toxicity
¥24,781.00/US$253.83 per 300-µg
injection
Levoﬂoxacin ¥475.30/US$4.87 per 500-mg tablet
Sodium ferrous citrate ¥5.60/US$0.06 per 50-mg tablet
Domperidone ¥5.60/US$0.06 per 10-mg tablet
Tranexamic acid ¥58.00/US$0.59 per 250-mg
injection
Goshajinkigan ¥11.80/$0.12 per 1-g granule
Valsartan ¥61.40/$0.63 per 40-mg tablet
Candesartan cilexetil ¥72.30/$US0.74 per 4-mg tablet
Daikenchuto ¥9.70/US$0.10 per 1-g granule
CPT Current Procedural Terminology, ESAs Erythropoiesis-stimulating agents, G-CSF Growth colony stimulating factors,
HCPCS Healthcare Common Procedure Coding System, ICD-9 International Classiﬁcation of Diseases 9th Revision, IV
Intravenous
a US Lowest wholesale acquisition cost from Truven Health Analytics (2013)
b Costs based on 2013 exchange rate monthly average of 97.63 Yen per one dollar [20]
c Japan costs from Hokenyaku Jiten Plus, 2013 April edition, Yakugyou Kenkyuu Kai, 2013
d Centers for Medicare and Medicaid Services (2013)
e Hokenyaku Jiten (保険薬辞典), published by Jihou (じほう), 2013
f US Hospital charges from HCUP.net (2013), inﬂated from 2011 US dollars to 2013 US dollars using the medical care
component of the Consumer Price Index (US Department of Labor, Bureau of Labor Statistics, 2013)
g Japan costs calculated using the unit costs for drugs used for toxicity management and input from a Japanese physician
1254 Adv Ther (2015) 32:1248–1262
component individually. Oral erlotinib was
assumed to be dosed for 3 cycles (21 days
each) and incur zero administration costs. The
systemic therapy dosing inputs for each
regimen are also shown in Table 2. Additional
treatment pattern assumptions included in
both models are the following: patients are
limited to one transfusion of each type; ESAs are
used every other cycle until the end of
induction therapy; epoetin alfa dosing differs
by brand name–Procrit (Janssen Products, LP) is
dosed at 150 units/kg three times every other
week and Epogen (Amgen) is dosed at 100 units/
kg three times every other week; darbepoetin
alfa is dosed at 500 g every 3 weeks; and G-CSFs
are given every cycle until the end of induction
therapy and is injected 6 mg every cycle.
In both cost comparison models, one-way
sensitivity analyses were conducted to examine
the effect of individual parameter changes on
model results. Additionally, probabilistic
sensitivity analyses using Monte Carlo
methods (10,000 iterations) were conducted to
model the joint uncertainty around model
parameters while scenario analyses tested
alternative model assumptions regarding costs.
Finally, a threshold analysis was conducted to
determine whether the additional increase in
price for pemetrexed and a decrease in price for
bevacizumab would result in equivalent costs.
Scenario analyses were conducted around those
cost parameters wherein assumptions had to be
made regarding utilization patterns for PemC
and PBC, including: (1) no subsequent therapy
costs were attributed to either PemC or PBC
after disease progression; (2) no subsequent
therapy, ESA, G-CSF, or transfusion costs were
incurred by either arm; (3) no subsequent
therapy, ESA, G-CSF, transfusion, or toxicity
costs were incurred by either arm; and (4) only
the cost of induction and maintenance drugs
Table 2 Study treatment and post-discontinuation
therapy based on the PRONOUNCE trial (US and
Japan models) [15]








Carboplatin (with PemC) 637.2 12.30
Carboplatin (with PCB) 628.2 12.97
Bevacizumab 1038.0 22.17









G-CSF utilization 15.8 26.5
Transfusions
Fresh frozen plasma 0.6 0.0









ESA Erythropoiesis-stimulating agent, G-CSF Growth
colony stimulating factor, PCB Induction bevacizumab
plus paclitaxel plus carboplatin followed by single-agent
bevacizumab, PemC Induction pemetrexed plus
carboplatin followed by single-agent pemetrexed, SE
Standard error
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for PemC or PBC were modeled. The US and
Japan models were designed and conducted in
concordance with International Society For
Pharmacoeconomics and Outcomes Research
(ISPOR) good practice guidelines [12, 13].
Cross-Country Comparison
The two models were compared across key
input and transferability factors as identified
in ISPOR guidance documents [12, 13]. These
points included: the decision problem; regional
treatment patterns; cost inputs; use of local
data; sensitivity analysis parameters; base case
results; and results of probabilistic and
sensitivity analyses. As both models were
completed in 2013, the Japanese Yen to US
dollar comparisons were based on a 2013
exchange rate monthly average of 97.63 Yen
per US $1 [20].
Compliance with Ethical Guidelines
This analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Both the US and Japan models approached the
decision problem of cost analysis in the setting
of a randomized trial (PRONOUNCE) in which
there were no statistically significant findings
for the study efficacy outcomes. Treatment
patterns were primarily based on the clinical
trial interventions, with the exception of the
care for toxicity, which was not mandated by
the phase III study protocol. The estimated costs
of grade 3–4 toxicity management were
consistently higher in the US than in Japan,
ranging from a difference of $4499 for vomiting
to a difference in cost of $25,728 for
thromboembolism. Cost inputs were
consistently identified, but cost per mg varied
between countries; bevacizumab and erlotinib
cost more in the US than in Japan and all other
chemotherapy agents cost more in Japan than
in the US.
A comparison of the base case scenarios for
the US and Japan models is presented in
Table 3. Despite the differences in cost
estimates of the key cost parameters (drug
costs and toxicity costs), the direction of the
models was consistent in the base case, with
the exception of the costs of chemotherapy
infusion, which were lower for PCB in the
Japan model while higher for PCB in the US
model. This is likely in part due to the
additional infusion time costs that can be
billed for drug administration in the US
(Table 1). In both models, drug acquisition
costs were identified in sensitivity analyses as
the primary contributor to the model
outcomes (Fig. 1). Other factors that
influenced outcomes in both models included
G-CSF use and duration of therapy. Other than
input costs, the parameters used for sensitivity
analyses were consistent between models.
Probabilistic sensitivity analyses found
directionally similar results despite the
country-specific cost parameters used in the
models. Figure 2 shows the mean, median, and
distribution of total costs when the range of
input parameters is varied. The cost ranges of
PemC and PCB were more similar in the US,
where the 25th and 75th percentiles overlap. In
comparison, for Japan there is a separation of
these ranges between PemC and PCB.
In the US, increasing the cost per mg for
pemetrexed by 43% (i.e., to $8.29 per mg)
resulted in PemC and PCB being approximately
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equivalent (PemC total costs = $73,974; PCB
total costs = $73,440). Further increases in unit
costs to pemetrexed would lead to PCB being
cost saving. Similarly, decreasing the cost per
mg for bevacizumab by 30% (i.e., to $4.35 per
mg) resulted in PemC and PCB being
approximately equivalent (PemC total
cost = $57,164; PCB total costs = $56,899).
Further decreases in unit costs to bevacizumab
would lead to PCB being cost saving. In Japan,
greater price changes were needed to reach
these thresholds. Increasing the cost per mg for
pemetrexed by 70% (to ¥612.77 per mg/US
$6.28 per mg) resulted in PemC and PCB being
approximately equivalent (PemC total
costs = ¥4,791,232/US$49,075; PCB total
costs = ¥4,824,345/US$49,414). Further
increases in unit costs to pemetrexed would
lead to PCB being cost saving. Similarly,
decreasing the cost per mg for bevacizumab by
53% (to ¥229.90 per mg/US$2.35 per mg)
resulted in PemC and PCB being
approximately equivalent (PemC total
cost = ¥3,084,146/US$31,590; PCB total
costs = ¥3,028,541/US$31,021). Further
decreases in unit costs to bevacizumab would
lead to PCB being cost saving.
Lastly, a comparison of the scenario analyses
is presented in Table 4. In Japan there was a
greater price differential leading to a higher
probability of cost savings with PemC than in
the US model, although both found PemC to be
more likely to be less costly across all proposed
scenarios.
Table 3 Base case results















Induction $17,380 $21,937 $4557 $12,141 $18,402 $6261
Maintenance $19,576 $23,830 $4254 $12,461 $17,053 $4592
Premedication $15 $15 $0 $83 $175 $93
Subsequent therapy $4990 $8810 $3820 $3217 $5948 $2730
First-line therapy
(induction + maintenance)
$1956 $2389 $433 $528 $524 $4
Subsequent therapy $407 $529 $122 $125 $166 ($41)
Toxicity $8970 $9700 $730 $99 $157 $58
G-CSF use $2128 $3472 $1344 $2765 $4512 $1747
ESA use $2047 $510 ($1537) $634 $189 ($445)
Transfusions $141 $55 ($86) $38 $15 ($24)
Total $57,609 $71,248 $13,639 $32,090 $47,140 $15,049
ESA Erythropoiesis-stimulating agent, G-CSF Growth colony stimulating factor, PCB Induction bevacizumab plus
paclitaxel plus carboplatin followed by single-agent bevacizumab, PemC Induction pemetrexed plus carboplatin followed by
single-agent pemetrexed
a Difference in 2013 $US; parentheses indicate negative values where PemC is more expensive; overall differences vary due
to rounding
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DISCUSSION
In a comparison of health care spending across
13 industrialized nations, the US was found to
have the highest per-capita spending on health
care, while Japan had the lowest [9]. The current
cost comparison study was designed to take into
account these large systematic differences in
national health care spending to understand
the implications at the level of a drug to drug
Fig. 1 One-way sensitivity analyses for US (above) and
Japan (below). G-CSF Granulocyte-colony stimulating
factor, PCB Induction bevacizumab plus paclitaxel plus
carboplatin followed by single-agent bevacizumab, PemC
Induction pemetrexed plus carboplatin followed by
single-agent pemetrexed
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comparison. Based on this assessment,
recommendations are made regarding the key
considerations when adapting clinical
trial-based models from one country to
another. Unless cost structures vary
dramatically between the agents under
consideration from country to country, cost
analyses may be expected to be directionally
consistent given the underlying clinical trial
parameters that remain unchanged. However,
even small price differences between countries
can have a relatively large impact on
probabilistic and threshold analyses.
There are a number of limitations of the
models used in this cross-country comparison,
as well as for the comparison between these US
and Japan-focused models. First, these cost
analyses are not likely to be directly
generalizable to a US payer or to the Japanese
national health care system, as the models were
based on the population and treatments used in
the PRONOUNCE clinical trial. Specifically, the
US model was designed from a third-party payer
perspective and the Japan model from a
hospital perspective. In the US model,
hospitalizations were not included directly in
the analysis as these were incorporated as part
of the cost of toxicities. The impact of
non-toxicity related hospitalizations is not
accounted for in the US model. While costs
were extracted from publicly available sources
for both models, in the US pricing structures
differ across organizations and the publicly
available costs may not reflect those used by
private insurance companies or for
reimbursement. For the Japan model, the
impact of private insurance costs was not
included. However, sensitivity analyses were
consistent across a wide variation in possible
drug acquisition prices in the US and Japan.
Additionally, the dose of docetaxel in this
model was 75 mg/m2, which while common
Fig. 2 Probabilistic sensitivity analyses for the US (a) and
Japan (b) models, mean (diamond), median (bar), range
(error bars) and 25–75% quartile (box height) total costs
based on 10,000 iterations. PCB Induction bevacizumab
plus paclitaxel plus carboplatin followed by single-agent
bevacizumab, PemC Induction pemetrexed plus
carboplatin followed by single-agent pemetrexed
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in the US, may be higher than the 60 mg/m2
dose that is more commonly used in Japan. As a
result, the cost of docetaxel may be slightly
higher than expected for this region. However,
the input costs of docetaxel for the additional
15 mg/m2 are very small given the generic costs
of this agent and the use of 75 versus 60 mg/m2
does not impact any of the results from this
study.
There are other factors that may influence
economic modeling across countries that could
not be directly compared in this study. This
study compared cost analyses across regions
from the same clinical trial, so differences in
outcomes were not a factor. While in a clinical
trial outcomes would be consistent regardless of
the region to which the model were adapted,
the use of quality-adjusted life years could
impact the outcomes differently by country.
For example, a country’s preference for use of
societal or patient-based utility weights to
adjust outcomes for quality and
country-specific algorithms for EQ-5D elicited
preference weights could affect the outcome
differently by region. Other factors that may
differ between countries that could not be
compared in this study include discount rates,
the inclusion versus exclusion of indirect costs,
and procedures that may be conducted in an
inpatient versus outpatient setting in the
different regions.
Despite these limitations, this comparison
demonstrates how even moderate differences in
pricing may affect outcomes. While the
direction of these two models remained
consistent between the US and Japan, there
were differences in results, with the cost savings
in Japan being more robust than in the US
model. This was a cost analysis; however, the
results of the cross-country comparison would
be unchanged in a cost-effectiveness analysis of
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the survival outcomes would not vary between
models even if they differ between treatment
arms. When adapting or applying a model from
one country to another, the factors outlined in
this report should be taken into consideration
for how the implications of one model may or
may not apply to another region.
This study was limited to the time frame of
the PRONOUNCE study. Future research is
needed to generate more generalizable cost
comparison data between these regimens using
real-world data. Such a study could demonstrate
how the cost and outcomes of these regimens
may compare in an uncontrolled setting. The
results of this study will be more applicable to
settings in which clinical practice patterns
follows the use of these regimens as prescribed
for the PRONOUNCE trial and are administered
within the populations that were eligible for
enrollment to the study.
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